Research Paper Volume 13, Issue 10 pp 14499—14521
Identification of a 15-pseudogene based prognostic signature for predicting survival and antitumor immune response in breast cancer
Figure 2. Expressions of prognostic pseudogenes in breast cancer by different clinicopathological features in TCGA dataset. (A) The distribution of risk score, vital status and the expression pattern of 15 prognostic pseudogenes in 775 breast cancer patients. The risk scores are arranged in ascending order from left to right. (B) Expression levels of NCF1C, HLA-DRB6, HLA-DPB2, HLA-J, HLA-H, HLA-L, RPL13AP20, PGM5P2, HERC2P4, HSP90AB2P, DHX40P1, RRN3P3, RRN3P2, SDHAP1 and RPL23AP53 across different breast cancer subtypes. (C) Expression levels of HLA-H, RPL13AP20, PGM5P2, HERC2P4 and RRN3P2 in patients with or without lymph node metastasis. (D) Expression levels of HLA-H, RPL13AP20, PGM5P2, HERC2P4 and RRN3P23 in patients with or without distant metastasis. (E) Univariate and multivariate Cox regression analyses of the association between clinicopathological factors (including the risk score) and overall survival of breast cancer patients. ns denotes no significance, *** denotes P < 0.001 and **** denotes P < 0.0001.